R-DHAOx regimen
WikiDoc Resources for R-DHAOx regimen |
Articles |
---|
Most recent articles on R-DHAOx regimen Most cited articles on R-DHAOx regimen |
Media |
Powerpoint slides on R-DHAOx regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on R-DHAOx regimen at Clinical Trials.gov Trial results on R-DHAOx regimen Clinical Trials on R-DHAOx regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on R-DHAOx regimen NICE Guidance on R-DHAOx regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on R-DHAOx regimen Discussion groups on R-DHAOx regimen Patient Handouts on R-DHAOx regimen Directions to Hospitals Treating R-DHAOx regimen Risk calculators and risk factors for R-DHAOx regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for R-DHAOx regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
R-DHAOx regimen refers to a regimen consisting of rituximab, dexamethasone, high-dose cytarabine (Ara-C), and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma.[1]
Regimen
RRituximab
DDexamethasone
HHigh Dose
ACytarabine (Ara-C)
OxOxaliplatin
Indications
References
- ↑ 1.0 1.1 Machover D, Delmas-Marsalet B, Misra SC, Ulusakarya A, Gumus Y, Frénoy N; et al. (2010). "Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma". Biomed Pharmacother. 64 (2): 83–7. doi:10.1016/j.biopha.2009.11.001. PMID 20044233.